Published in Scientific Papers. Series D. Animal Science, Vol. LXII, Issue 1
Written by Nicoleta Mirela BLEBEA, Teodor COSTACHE, Simona NEGREȘ
Cannabidiol (CBD) is the major non-psychotropic cannabinoid compound derived from the plant Cannabis sativa L. CBD was first isolated in 1940 and its structure and stereo chemistry determined in 1963. The cannabinoid CBD, a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. In just a few years, cannabidiol (CBD) has become immensely popular around the world, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases(Hazekamp, 2018). Hemp oil from Cannabis sativa L. is a very rich natural source of important nutrients, not only polyunsaturated fatty acids and proteins, but also terpenes and cannabinoids, which contribute to the overall beneficial effects of the oil. In the European Union (EU), the cultivation of certain cannabis varieties is granted provided they are registered in the EU’s Common Catalogue of Varieties of Agricultural Plant Species and the THC content does not exceed 0.2% of the dried flowers of the plant(European Commission website, 2018). There are hundreds of producers and sellers of CBD oils active in the market, and their number is increasing rapidly. Various studies done on CBD oils products around the world have come to similar conclusions about incorrect label information. For that reason, thorough analytical testing of final products by certified third-party labs is an essential tool to guarantee the safety and composition of CBD oils. Hence, it is important to have an analytical method for the determination of these components in commercial samples and their applications. The present work describes a technique for the monitoring the cannabidiol-CBD present in 3 commercial hemp oils, by UHPLC with PDA detection.
[Read full article] [Citation]
